glp 1 vs glucagon GLP-1 Agonists: Increasing Effective Insulin Release Use of Glucagon-Like Peptide-1 |

Therefore, given the widespread use of incretin agonists for obesity treatment and weight loss, it is important to recognize their effects in the gastrointestinal tract, which could constitute significant benefits in weight loss and cardiometabolic benefits, but can be associated with adverse effects that constitute a potential barrier to their use, particularly at higher doses

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach

A 2025 pilot study infused up to 20 mg of BPC157 intravenously in 2 healthy adults and reported no adverse effects and no abnormal changes in heart, liver, kidney, thyroid, or bloodglucose markers

Streaks and Journey Cards reward consistency during slow weeks, not just dramatic weigh-ins